Sonnet BioTherapeutics Holdings, Inc. - Common Stock (SONN)
1.2600
+0.00 (0.00%)
NASDAQ · Last Trade: Dec 3rd, 9:52 PM EST
Detailed Quote
Previous Close
1.260
Open
-
Bid
1.000
Ask
1.030
Day's Range
N/A - N/A
52 Week Range
1.080 - 19.30
Volume
0
Market Cap
8.51M
PE Ratio (TTM)
-0.1785
EPS (TTM)
-7.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
762,004
Chart
About Sonnet BioTherapeutics Holdings, Inc. - Common Stock (SONN)
Sonnet Biotherapeutics Holdings Inc is a biotechnology company focused on the development of innovative therapies for various diseases, particularly in the field of immuno-oncology. The company leverages its proprietary technology platform to create biologic drugs that aim to harness the body's immune system to target and eliminate cancer cells. Through a combination of advanced engineering and scientific expertise, Sonnet is working to deliver novel treatments that could provide meaningful benefits to patients in need, addressing unmet medical needs in oncology and other therapeutic areas. Read More
A major fund just opened a multimillion-dollar position in ImmunityBio—and the move could hint at rising confidence in this clinical-stage immunotherapy pipeline.
One fund just walked away from American Superconductor—but the company’s role in the future of grid resiliency might be more important than any single quarterly filing suggests.
Hyperliquid (CRYPTO: HYPE) jumped 10% to $39.70 on Thursday after Hyperliquid Strategies Inc. filed a Form S-1 with the SEC, seeking to raise up to $1 billion through a 160 million-share public offering that could also fund token purchases linked to
HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid (PDT) platforms that emulate the tumor microenvironment (TME) ex vivo to evaluate the effect of SON-1010 (IL-12-FHAB) in soft tissue sarcoma. The study aims to speed up the development of treatments for patients with rare and difficult-to-treat cancers.
